Results 161 to 170 of about 856,598 (307)

Spatiotemporal Sequential Delivery of Chidamide Regulates Macrophage Reprogramming in Lymphoma Microenvironment Through HDACs‐STAT3 Pathway

open access: yesAdvanced Science, EarlyView.
Our study identifies the HDACs‐STAT3 axis as key regulator for M2 macrophage accumulation in DLBCL. We developed Chid@M2pep‐EVs/TP, a pH‐responsive drug delivery system for M2 macrophage specific chidamide administration. By coupling M2‐targeted chidamide with EVs‐mediated delivery, this system reprograms M2 to M1 via HDAC inhibition and STAT3 ...
Bo Dai   +15 more
wiley   +1 more source

A political economy model of road pricing [PDF]

open access: yes
In this paper, we take a political economy approach to study the introduction of urban congestion tolls, using a simple majority voting model. Making users pay for external congestion costs is for an economist an obvious reform, but successful ...
Bruno DE BORGER, Stef PROOST
core  

Highlighting Recent Progress in Fiber Energy Harvesters: From Working Principles to Future Perspectives

open access: yesAdvanced Science, EarlyView.
Fiber energy harvesters offer unprecedented flexibility and a unique capacity for integration into commercial textiles, overcoming the limitations of bulky and rigid conventional devices. This review summarizes recent advances in fiber‐based energy harvesting and provides strategic outlooks to accelerate technological progress in the field. ABSTRACT As
Hanhwi Jang   +8 more
wiley   +1 more source

Ovarian Matrisome Dynamics and αvβ3‐Mediated Regulation in Early Follicular Development

open access: yesAdvanced Science, EarlyView.
The matrisome undergoes dynamic remodeling during early follicular development. Integrin αvβ3 mediates matrisome signals, regulating primordial follicle activation/atresia and secondary follicle growth via Hippo/mTOR pathways, with conserved roles in human ovaries, offering therapeutic targets for ovarian disorders.
Tong Wu   +12 more
wiley   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy